SYN 200
Alternative Names: SYN-200Latest Information Update: 14 Oct 2022
At a glance
- Originator Synthetic Biologics
- Developer Theriva Biologics
- Class Peptide hormones; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Phenylketonuria
Most Recent Events
Development Overview
Introduction
Theriva Biologics (formerly Synthetic Biologics), in collaboration with Precigen Inc (formerly Intrexon Corporation), are developing SYN 200, a novel biotherapeutics for the treatment of patients with phenylketonuria. The company will utilise Intrexon's ActoBiotics™ platform, a proprietary method of delivering therapeutic protein and peptides to the gastrointestinal (GI) tract through food-grade microbes. The product is designed to deliver a key enzyme to facilitate the breakdown of phenylalanine and thereby prevent the toxicity in these patients. The programme is in the research stage.
As at October 2019, no recent reports of development had been identified for research development in Phenylketonuria in USA (PO).
In February 2020, Intrexon Corporation has changed its name to Precigen Inc [1] .
In October 2022, Synthetic Biologics changed its name to Theriva Biologics [2] .
Company Agreements
In August 2015, Intrexon and Synthetic Biologics entered into an Exclusive Channel Collaboration (ECC), wherein the latter will utilise Intrexon's ActoBiotics™ biotherapeutics platform for the development and commercialisation of novel biotherapeutics for the treatment of patients with phenylketonuria. In connection with the ECC, Synthetic Biologics paid Intrexon, a technology access fee equalling to $US3 million (Synthetic Biologics, form 10-K, March 2016) [3] .
Key Development Milestones
In August 2015, pursuant to the exclusive channel collaboration with Intrexon, Synthetic Biologics initiated the SYN 200 programme for development and commercialisation of novel biotherapeutics for the treatment of patients with phenylketonuria (Synthetic Biologics, form 10-K, March 2016).
Drug Properties & Chemical Synopsis
- Route of administration PO
- Formulation unspecified
- Class Peptide hormones, Proteins
- Mechanism of Action Undefined mechanism
-
WHO ATC code
A16A (Other Alimentary Tract and Metabolism Products)
-
EPhMRA code
A16A (Other Alimentary Tract and Metabolism Products)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Phenylketonuria | - | - | No development reported (Research) | USA | PO / unspecified | Theriva Biologics | 28 Oct 2019 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Synthetic Biologics | Originator | USA |
| Theriva Biologics | Owner | USA |
| Precigen Inc | Technology Provider | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 12 Oct 2022 | Company Involvement | Synthetic Biologics is now called Theriva Biologics [2] Updated 14 Oct 2022 |
| 03 Feb 2020 | Company Involvement | Intrexon Corporation is now called Precigen Inc Updated 11 Feb 2020 |
| 28 Oct 2019 | Phase Change - No development reported | No recent reports of development identified for research development in Phenylketonuria in USA (PO) Updated 28 Oct 2019 |
| 10 Aug 2015 | Licensing Status | Intrexon and Synthetic Biologics enter into an Exclusive Channel Collaboration to develop and commercialise ActoBiotics™ biotherapeutics for Phenylketonuria [3] Updated 20 Jun 2016 |
| 01 Aug 2015 | Phase Change | Early research in Phenylketonuria in USA (PO) Updated 20 Jun 2016 |
References
-
Precigen Completes Series Of Transactions To Solidify Healthcare Focus.
Media Release -
Synthetic Biologics Rebrands as Theriva Biologics.
Media Release -
Intrexon and Synthetic Biologics Enter ECC to Develop Novel Biotherapeutics for Treatment of Phenylketonuria.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG